Arcutis presents roflumilast data across three skin conditions at EADV

Arcutis shared Phase 2 infant atopic dermatitis data and real-world corticosteroid research at two major dermatology conferences this month.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A brightly lit infusion room features three empty beige recliners, each with an IV pole and side table, separated by clear dividers, and large windows overlooking a blurred green landscape.

Arcutis Biotherapeutics used back-to-back dermatology congresses in October to advance the evidence base for its roflumilast franchise, presenting data from a Phase 2 infant study, two psoriasis subanalyses, and new collaborative research into the biology of seborrheic dermatitis. The Nasdaq-listed company also unveiled, for the first time at a medical congress, real-world survey data on topical corticosteroid use, a category it is positioning ZORYVE (roflumilast) to displace.

The headline dataset came from INTEGUMENT-INFANT, a Phase 2 study of once-daily ZORYVE cream 0.05% in 101 infants aged 3 to less than 24 months with atopic dermatitis. Among the 96 infants who completed four weeks of treatment, 34.4% achieved validated investigator global assessment success, defined as clear or almost clear skin with at least a two-grade improvement from baseline. Scalp clearance was higher, with 67.5% meeting the same threshold on the IGA-Scalp measure. No serious adverse events were reported, and application-site irritation was absent in at least 97.9% of participants. Separately, caregivers reported that 46.6% of infants showed at least a 25% improvement in itch within ten minutes of the first application.

The infant formulation is under FDA review, with a PDUFA target action date of 23 February 2027. An approval would extend the labelled indication below the current floor of two years of age for the 0.05% cream.

Psoriasis and seborrheic dermatitis findings

Two analyses drawn from the Phase 3 ARRECTOR and DERMIS-1/2 trials addressed psoriasis in difficult-to-treat anatomical sites. In the ARRECTOR subanalysis of 432 patients aged 12 and older, 66.4% of those using ZORYVE foam 0.3% achieved clear or almost clear scalp skin at week eight, against 27.8% for vehicle; body clearance rates were 45.5% versus 20.1%. Within 24 hours of the first dose, the foam group showed meaningfully greater reductions in both scalp itch and worst itch scores compared with vehicle. A companion analysis of DERMIS-1/2 and ARRECTOR data found that roflumilast cream and foam improved patient-reported sexual function and personal relationships by week eight, in populations with and without genital psoriasis at baseline, an outcome dimension that regulators and payers increasingly regard as clinically meaningful.

Collaborative research from Mount Sinai, presented at EADV, used proteomic analysis of tape strips and skin biopsies to characterise seborrheic dermatitis as a primarily Th17-mediated disease, distinguishing it molecularly from atopic dermatitis. The data were framed by Arcutis as supporting the potential role of PDE4 inhibition in this indication, where roflumilast foam is already approved.

Corticosteroid hesitancy as a commercial narrative

Arcutis also presented real-world survey data developed with the National Eczema Association and the National Psoriasis Foundation, covering 1,000 adults and 500 caregivers of children prescribed topical corticosteroids. The results document widespread corticosteroid hesitancy: nearly half of adults (47.8%) and caregivers (45.0%) said they had not raised concerns about long-term steroid use with their prescriber. Hesitancy was significantly higher among those who had previously experienced an adverse reaction, and a companion literature review identified Cushing's syndrome features in 47.6% of case reports and publications reviewed over the past decade.

The framing is strategically transparent. Arcutis is using independently sourced patient survey data to reinforce the case for a non-steroidal alternative in the three indications where ZORYVE is already marketed. The topical PDE4 inhibitor space remains relatively uncrowded: Pfizer's crisaborole, the earlier entrant, has faced prescriber pushback on tolerability, and Eli Lilly's lebrikizumab and AbbVie's dupilumab compete in atopic dermatitis but operate via distinct mechanisms and administration routes. Roflumilast's once-daily topical profile and multi-indication label give Arcutis a differentiated position, particularly in paediatrics where systemic options carry additional scrutiny.

Near-term catalysts include the February 2027 PDUFA date for the infant indication and any further Phase 3 data readouts across the seborrheic dermatitis pipeline.

Sector

Topic

Geography